The FDA has approved the supplemental Biologics License Application (sBLA) for Vectibix (panitumumab), from Amgen, for patients with wild-type RAS...
The committee for medicinal products for human use of the European Medicines Agency has adopted a positive opinion to extend...
Amgen announced that the European Commission approved a new use of Vectibix (panitumumab) as first-line treatment in combination with FOLFIRI...